SEARCH

SEARCH BY CITATION

REFERENCES

  • Angell M. 2000. The pharmaceutical industry — to whom is it accountable? New England Journal of Medicine 342: 19021904.
  • Arcidiacono P, Ellickson PB, Landry P, Ridley DB. 2013. Pharmaceutical followers. Duke University Working Paper.
  • Avorn J. 2006. Part ‘D’ for ‘defective’ — the Medicare drug-benefit chaos. New England Journal of Medicine 354: 13391341.
  • Azoulay P. 2002. Do pharmaceutical sales respond to scientific evidence? Journal of Economics & Management Strategy 11(4): 551594.
  • Baicker K, Goldman D. 2011. Patient cost-sharing and healthcare spending growth. Journal of Economic Perspectives 25(2): 4768.
  • Berndt ER, Bui L, Reiley DR, Urban GL. 1995. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85(2): 100105.
  • Berndt ER, Pindyck RS, Azoulay P. 2003. Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs. Journal of Industrial Economics 51(2): 243270.
  • Bradford WD, Kleit AN, Nietert PJ, Steyer T, McIlwain T, Ornstein S. 2006. How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. Health Affairs 25(5): 13711377.
  • Centers for Medicare and Medicaid Services. 2008. Medicare Prescription Drug Benefit's Projected Costs Continue To Drop. Press Release.
  • Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. 2008. Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs 27(1): 103112.
  • Ching AT, Ishihara M. 2010. The effects of detailing on prescribing decisions under quality uncertainty. Quantitative Marketing and Economics 8(2): 123165.
  • Ching AT, Ishihara M. 2012. Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Science 58(7): 13741387.
  • Chintagunta PK, Jiang R, Jin GZ. 2009. Information, learning, and drug diffusion: the case of Cox-2 inhibitors. Quantitative Marketing and Economics 7(4): 399443.
  • Crawford GS, Shum M. 2005. Uncertainty and learning in pharmaceutical demand. Econometrica 73(4): 11371173.
  • Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. 2004. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 42(12): 11761185.
  • Dor A, Encinosa W. 2010. How does cost-sharing affect drug purchases? Insurance regimes in the private market for prescription drugs. Journal of Economics & Management Strategy 19(3): 545574.
  • Duggan M, Scott Morton F. 2010. The effect of Medicare part D on pharmaceutical prices and utilization. American Economic Review 100(1): 590607.
  • Febbo W. 2005. Managed care confidential. Pharmaceutical Executive.
  • Frank RG, Newhouse JP. 2008. Should drug prices be negotiated under part D of Medicare? And if so, how? Health Affairs 27(1), 3343.
  • Galewitz P. 2009. Seniors often reluctant to switch Medicare drug plans. Kaiser Health News.
  • Gemmill MC, Costa-Font J, McGuire A. 2007. In search of a corrected prescription drug elasticity estimate: a meta-regression approach. Health Economics 16(6): 627643.
  • Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM. 2004. Pharmacy benefits and the use of drugs by the chronically Ill. Journal of the America Medical Association 291(19): 23442350.
  • Gönül FF, Carter F, Petrova E, Srinivasan K. 2001. Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing 65(3): 7990.
  • Gury M. 2003. IMS reports 8 percent constant dollar growth in 2002. Audited global pharmaceutical sales to $400.6 billion. IMS Health.
  • Hensley S. 2005. Drug makers seek to transform advertising. Wall Street Journal.
  • Iizuka T, Jin GZ. 2005. The effect of prescription drug advertising on doctor visits. Journal of Economics & Management Strategy 14(3): 701727.
  • Iizuka T, Jin GZ. 2007. Direct-to-consumer advertising and prescription choice. Journal of Industrial Economics 55(4): 771.
  • Jena AB, Calfee JE, Mansley EC, Philipson TJ. 2009. ‘Me-too’ innovation in pharmaceutical markets. Forum for Health Economics & Policy 12(1): 119.
  • Joseph K, Mantrala M. 2009. A model of the role of free drug samples in physicians' prescription decisions. Marketing Letters 20(1): 1529.
  • Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. 2000. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Alimentary Pharmacology and Therapeutics 1(10): 12491258.
  • Kaiser Family Foundation. 2010. Prescription drug benefits. Employer Health Benefits 2010 Annual Survey, 143152.
  • Ketcham JD, Simon KI. 2008. Medicare part D's effects on elderly drug costs and utilization. American Journal of Managed Care 14(11): SP1422.
  • Lee I-H, Bloor K, Hewitt C, Maynard A. 2012. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Health Policy 104(1): 4049.
  • Leibowitz A, Manning WG, Newhouse JP. 1985. The demand for prescription drugs as a function of cost-sharing. Social Science and Medicine 21(10): 10631069.
  • Lichtenberg FR, Philipson TJ. 2002. The dual effects of intellectual property regulations: within- and between-patent competition in the U.S. pharmaceuticals industry. Journal of Law and Economics 45(2): 643672.
  • Ling DC, Berndt ER, Kyle MK. 2002. Deregulating direct-to-consumer marketing of prescriptions drugs: effects of prescription and over-the-counter product sales. Journal of Law and Economics 45: 691723.
  • Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A. 1987. Health insurance and the demand for medical care: evidence from a randomized experiment. American Economic Review 77(3): 251277.
  • Neslin S. 2001. ROI Analysis of Pharmaceutical Promotion (RAPP): an independent study. Slide presentation on Internet 123.
  • Pharmaceutical Research and Manufacturers of America. 2005. PhRMA guiding principles direct to consumer advertisements about prescription medicines.
  • Ridley DB, Axelsen KJ. 2006. Impact of Medicaid preferred drug lists on therapeutic adherence. PharmacoEconomics 24Suppl 3: 6578.
  • Rizzo JA. 1999. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. Journal of Law and Economics 42: 89116.
  • Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG. 2003. Demand effects of recent changes in prescription drug promotion. The Henry J. Kaiser Family Foundation Paper 6085, 133.
  • Seman J. J. 2003. In search of preferred status. Pharmaceutical Executive.
  • Slaughter LM. 2006. Medicare part D — the product of a broken process. New England Journal of Medicine 354: 23142315.
  • Venkataraman S, Stremersch S. 2007. The debate on influencing doctors' decisions: are drug characteristics the missing link? Management Science 53(11): 16881701.
  • Windmeijer F, de Laat E, Douven R, Mot E. 2006. Pharmaceutical promotion and GP prescription behaviour. Health Economics 15(1): 518.
  • Wosinska M. 2002. Just what the patient ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products. Harvard Business School Marketing Research Paper Number 02–04, 144.
  • Wroblewski MS. 2005. Pharmacy benefit managers: ownership of mail-order pharmacies. United States Federal Trade Commission.